真实世界研究:奥西洛司他在非垂体性库欣综合征的疗效与安全性
本研究为法国多中心回顾性观察研究,纳入103例非垂体性库欣综合征成人患者,评估奥西洛司他真实世界疗效与安全性。第12周时44.2%(95%CI 30.5%-58.7%)患者平均尿游离皮质醇≤正常上限。最常见不良事件为肾上腺功能不全(28%)和低钾血症(18%)。
要点
- 奥西洛司他可降低非垂体性库欣综合征患者皮质醇水平,第4周起效并维持稳定。
- 第12周44.2%患者平均尿游离皮质醇≤正常上限,缺失值按无应答处理。
- 常见不良事件为肾上腺功能不全(28%)和低钾血症(18%),需监测。
核心结论
- 奥西洛司他是多种非垂体病因内源性库欣综合征的合适治疗选择。
研究设计与样本
- 法国多中心回顾性观察研究(LINC 7;NCT05633953),纳入103例成人非垂体性库欣综合征患者,包括异位ACTH综合征53例、肾上腺皮质癌19例、肾上腺腺瘤17例、双侧肾上腺结节病14例。
主要发现
- 第12周有平均尿游离皮质醇数据的52例中,异位ACTH综合征12/29(41%)、肾上腺皮质癌4/6、肾上腺腺瘤1/3、双侧肾上腺结节病6/7达到≤正常上限。
- 最常见(≥15%)治疗中出现的不良事件为肾上腺功能不全(28%)和低钾血症(18%)。
- 29例患者死亡(异位ACTH综合征24例,肾上腺皮质癌5例),最常见死因为肿瘤进展(11例),仅1例死亡被研究者评估为与奥西洛司他相关。
关键数值与推荐
- 奥西洛司他起始和滴定基于研究者判断。
- 中位(最小-最大)奥西洛司他暴露时间为177天(1-1178天),基线剂量为5.0 mg/天(1-60 mg/天)。
临床怎么用
- 奥西洛司他可考虑用于非垂体性库欣综合征的皮质醇控制,治疗中需监测肾上腺功能不全和低钾血症。
局限性
- 回顾性观察设计,样本量有限,部分病因亚组例数少。
- 缺失值按无应答处理可能低估疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Osilodrostat's clinical development program mostly enrolled Cushing disease patients. Data in nonpituitary Cushing syndrome (CS) patients are limited. OBJECTIVE: This work aims to evaluate osilodrostat effectiveness and safety in nonpituitary CS in real-world practice in France. METHODS: A retrospective, observational study (LINC 7; NCT05633953) was conducted in a multicenter institutional practice setting. Data for patients who initiated osilodrostat under the French Autorisation Temporaire d'Utilisation program or, once approved, in routine clinical practice were extracted retrospectively for 36 months or less (2019-2022). Participants included 103 adult nonpituitary CS patients: ectopic adrenocorticotropin secretion (EAS), n = 53; adrenocortical carcinoma (ACC), n = 19; adrenal adenoma (AA), n = 17; and bilateral adrenal nodular disease (BND), n = 14. Forty-three patients remained on osilodrostat throughout the observation period. Median (minimum-maximum) osilodrostat exposure and baseline dose were 177 days (1-1178 days) and 5.0 mg/day (1-60 mg/day), respectively. The main outcome measure was the proportion with mean urinary free cortisol (mUFC) less than or equal to the upper limit of normal (ULN) at Wk 12 (modified intention-to-treat [mITT] population: all enrolled patients with ≥12 weeks' follow-up, excluding patients without Wk 12 mUFC for nonsafety reasons). RESULTS: Osilodrostat was initiated and titrated based on investigator judgment. Cortisol decreased by Wk 4, remaining stable thereafter. Twenty-three of 52 patients (mITT, 44.2%; 95% CI, 30.5%-58.7%) had mUFC less than or equal to the ULN at Wk 12 (missing values reported as nonresponders). Forty-five of 52 had Wk 12 mUFC available; the proportions with mUFC less than or equal to the ULN by etiology were as follows: EAS, n = 12/29 (41%); ACC, n = 4/6; AA, n = 1/3; and BND, n = 6/7. The most common (≥15%) treatment-emergent adverse events were adrenal insufficiency (28%) and hypokalemia (18%). Twenty-nine patients (EAS, n = 24; ACC, n = 5) died from adverse events (n = 1 assessed as osilodrostat related by investigator), most commonly neoplasm progression (n = 11). CONCLUSION: Osilodrostat is a suitable treatment for endogenous CS of various nonpituitary etiologies.
引用
- Tabarin A, Bertherat J, Decoudier B, et al. Real-World Osilodrostat Effectiveness and Safety in Nonpituitary Cushing Syndrome. J Clin Endocrinol Metab. 2026. PMID: 41260612. doi:10.1210/clinem/dgaf633
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。